This week we take a deep dive into two recently published studies, their surrounding controversy, and the broader implications. The first study was published in the journal Proceedings of the National Academy of Sciences of the USA and is titled "Physician–patient racial concordance and disparities in birthing mortality for newborns". The second was published in the New England Journal of Medicine and is titled "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer", commonly known as the HERO trial. We discuss the HERO trial with Dr. Michael Burns of Northwestern as part of our new segment, Journal Club with a Fellow.

Racial Concordance: doi.org/10.1073/pnas.1913405117

HERO: doi.org/10.1056/NEJMoa2004325

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

We have a lot in store for you this week! We start off by evaluating two recently published studies: "Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer" (published in the Journal of Clinical Oncology: Oncology Practice) and "The Effect of Advances in Lung-Cancer Treatment on Population Mortality" (published in the New England Journal of Medicine). We talk a bit about tracking down the validity of a reference. We sit down with Dr. Branden Tarlow to discuss his thoughts on PPIs and COVID-19 acquisition. Finally, we conclude the episode by interviewing Dr. Elizabeth Eisenhauer of Queen's University in Kingston, Ontario, Canada on her career in cancer medicine.

Omics-Based Strategies: doi.org/10.1200/OP.20.00117

Population Mortality: doi.org/10.1056/NEJMoa1916623

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

We start this week's episode by discussing access to investigational COVID-19 vaccines and recapping the problems with the ADAURA study. We transition from there to a Question of the Week with medical student Audrey Tran of Oregon Health & Science University. Finally, we introduce a new segment - Journal Club with a Fellow. In this inaugural segment we invite Dr. Karine Tawagi of the Oschner Clinic in Louisiana to the podcast to talk about IMbrave150.

IMbrave150: doi.org/10.1056/NEJMoa1915745

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

This is the recording of a LIVE episode of Plenary Session in which Dr. Sue S Yom interviewed our host, Dr. Vinay Prasad, on how he built his career and how he conceptualizes his work. There's also a surprise guest near the end! Thank you to Dr. Kaleigh Doke, Dr. Brian Kavanagh, and the Virtual Visiting Professor Network for hosting this special episode.

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

This week we respond to several questions sent in by listeners and then we interview Dr. Bishal Gyawali of Queen's University in Kingston, Ontario, Canada on MedTwitter, other recent events, and his recently published paper titled "Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials".

Ramucirumab: doi.org/10.1016/j.eclinm.2020.100458

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

This week we discuss two major papers: The first was just recently released in Nature and it's titled "The National Lung Matrix Trial of personalized therapy in lung cancer". The second is a few years old, but exemplifies the importance of trial design. We discuss the second paper, titled "A Randomized Trial of Intensive versus Standard Blood-Pressure Control" and published in the New England Journal of Medicine with Dr. Mark Friedberg, a health policies and performance measurement researcher.

National Lung Matrix Trial: doi.org/10.1038/s41586-020-2481-8

SPRINT: doi.org/10.1056/NEJMoa1511939

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

This week's BONUS episode is a discussion of the National Clinician Scholars Program with Dr. Hilary Seligman, the head of the program at University of California, San Francisco. The deadline for the application for the 2021-2023 cohort is July 15, 2020 (very soon!), though there may be some leniency due to the pandemic.

National Clinician Scholars Program: https://nationalcsp.org/

UCSF National Clinician Scholars Program: https://nationalscholars.ucsf.edu/

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

This week we discuss recent research (and the accompanying Twitter thread) on the risk of COVID-19 among users of proton pump inhibitors (PPIs). We also hold a philosophical discussion on the research surrounding time to treatment initiation (TTI) in cancer medicine. We end the episode with an interview with Dr. Lynora Saxinger of the University of Alberta, Edmonton, a specialist in Infectious Diseases.

PPIs and risk of COVID-19: https://twitter.com/BrennanSpiegel/status/1280527527325265920

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

This BONUS episode is the recording of a lecture given on June 18, 2020 as part of Stanford's METRICS International Forum. METRICS stands for Meta-Research Innovation Center at Stanford University. This lecture is geared towards a broad audience and aims to provide a general sense of current cancer research. The lecture is titled "Cancer Meta-Research 101".

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

This week we respond to some listener feedback from Dr. Christopher Booth and use it to talk about how to be the best hematologist-oncologist. We also discuss the SADAL study on Selinexor for patients with relapsed refractory diffuse large B-cell lymphoma, as published in The Lancet Haematology.

Finally, we interview Drs. Eva Katsoulakis and Michael Kelley on their recent paper out in the Journal of Clinical Oncology: Precision Oncology, titled "Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program".

Selinexor: doi.org/10.1016/S2352-3026(20)30120-4

Annotation Services: doi.org/10.1200/PO.19.00118

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: https://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew